Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications
2017 ◽
Vol 9
(4)
◽
pp. 287-298
◽
Keyword(s):
Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC.
2015 ◽
Vol 33
(15_suppl)
◽
pp. e15625-e15625
2010 ◽
Vol 51
(11)
◽
pp. 1707-1715
◽
2005 ◽
Vol 173
(4S)
◽
pp. 99-99
◽
2004 ◽
Vol 171
(4S)
◽
pp. 467-467
◽
Keyword(s):
2014 ◽
Vol 48
(4)
◽
pp. 379-386
◽